Mylan will take its offer to Irish-based Perrigo shareholders in the coming weeks. Photograph: Travis Dove/The New York Times

Mylan’s shareholders voted in favour of moving forward with a $33 billion (€29.5 billion) hostile bid for over-the-counter pharma group Perrigo, putti(...)

Perrigo chief executive Joseph Papa: “Mylan’s approach demonstrates an act of desperation.”

Mylan shareholders will on Tuesday decide on the generic drug maker’s bid to acquire Dublin-based rival Perrigo. Mylan is trying to acquire Perrigo in(...)

Joe Papa, chief executive  and president of Perrigo, which is fighitng off the unwatned advances of rival Mylan. Photograph: Brenda Fitzsimons / THE IRISH TIMES

Mylan appeared to hit a significant hurdle in its quest to buy a fellow drug maker, Perrigo, when an influential advisory firm recommended Friday morn(...)

Privately, some shareholders have been scathing about the tactics Mylan used to defend itself from a hostile takeover  by Teva. Photograph: Getty Images

Mylan, the generic drugs group, has launched a staunch defence of the tactics it used to repel a $40 billion hostile takeover attempt by Teva, amid po(...)

IAG’s takeover of Aer Lingus was one of the biggest M&A deals recorded in the first six months of 2015

M&A activity in Ireland fell in the first half of 2015, according to a new review. A total of 45 mergers and acquisitions worth €35.1 billion took(...)

Teva Pharmaceutical has built a 4.6 per cent share of Mylan over the past months. Photographer: Akos Stiller/Bloomberg

Teva Pharmaceutical, the Israeli drugmaker, is nearing a deal to acquire Allergan’s generics drug unit for between $40 billion and $45 billion, accord(...)

Sales in the company’s established pharmaceutical products business, which includes branded generics, rose 31.3 per cent

Abbott Laboratories, which employs almost 3000 people in Ireland, reported a slightly better-than-expected quarterly profit, helped by higher sales o(...)

Perrigo chief executive and chairman Joe Papa.  Photograph: Brenda Fitzsimons / The Irish Times

Perrigo, the Irish specialist in over the counter drugs, has agreed to buy a portfolio of products from GlaxoSmithKline. GSK’s consumer healthcare div(...)

Robert J. Coury, vice chairman and chief executive officer of Mylan told investors he may sweeten the company’s cash-and-stock offer for  Perrigo, which has rejected Mylan’s most recent offer of $75 in cash and 2.3 Mylan shares for each Perrigo share. (Photograph: Mannie Garcia/Bloomberg News)

Mylan’s chairman told investors he may sweeten the company’s cash-and-stock offer for Irish headquartered Perrigo by adding terms to reduce the risk (...)

Robert J. Coury, vice-chairman and chief executive of Mylan. Photographer: Mannie Garcia/Bloomberg News

Generic drugs group Mylan boosted its cash-and-stock offer to buy Irish company Perrigo to $34.10 billion, but the bid was swiftly rejected.Mylan’s p(...)